The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
Open accessAbstract
There are conflicting reports as to whether malignant peripheral nerve sheath tumor (MPNST) patients with neurofibromatosis type 1 (NF1) have worse prognosis than non-NF1 MPNST patients. Large clinical studies to address this problem are lacking due to the rareness of MPNST. We have performed meta-analyses testing the effect of NF1 status on MPNST survival based on publications from the last 50 years, including only nonoverlapping patients reported from each institution. In addition, we analyzed survival characteristics for 179 MPNST patients from 3 European sarcoma centers. The meta-analyses including data from a total of 48 studies and >1800 patients revealed a significantly higher odds ratio for overall survival (OR(OS)) and disease-specific survival (OR(DSS)) in the non-NF1 group (OR(OS) = 1.75, 95% confidence interval [CI] = 1.28-2.39, and OR(DSS) = 1.68, 95% CI = 1.18-2.40). However, in studies published in the last decade, survival in the 2 patient groups has been converging, as especially the NF1 group has shown improved prognosis. For our own MPNST patients, NF1 status had no effect on overall or disease-specific survival. The compiled literature from 1963 to the present indicates a significantly worse outcome of MPNST in patients with NF1 syndrome compared with non-NF1 patients. However, survival for the NF1 patients has improved in the last decade, and the survival difference is diminishing. These observations support the hypothesis that MPNSTs arising in NF1 and non-NF1 patients are not different per se. Consequently, we suggest that the choice of treatment for MPNST should be independent of NF1 status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K., & Mertens, F. (2002) · Lund University Publications (Lund University) · Cited by 4,294
Self-citationEnzinger and Weiss's Soft Tissue Tumors
Weiss, S. W., & Goldblum, J. R. (2001) · Cited by 2,510
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
Ducatman, B. S., Scheithauer, B. W., Piepgras, D. G., Reiman, H. M., & Ilstrup, D. M. (1986) · Cancer · doi:10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6 · Cited by 1,581
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Gene for von Recklinghausen Neurofibromatosis Is in the Pericentromeric Region of Chromosome 17
Barker, D., Wright, E., Nguyen, K., Cannon, L., Fain, P., Goldgar, D., Bishop, D. T., Carey, J., Baty, B., Kivlin, J., et al. (1987) · Science · doi:10.1126/science.3107130 · Cited by 695
Long-Term Follow-up of von Recklinghausen Neurofibromatosis
Sørensen, S. A., Mulvihill, J. J., & Nielsen, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604173141603 · Cited by 617
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
Ferner, R. E., & Gutmann, D. H. (2002) · PubMed · Cited by 603
Mortality in Neurofibromatosis 1: An Analysis Using U.S. Death Certificates
Rasmussen, S. A., Yang, Q., & Friedman, J. M. (2001) · The American Journal of Human Genetics · doi:10.1086/320121 · Cited by 530
Messiaen, L. M., Callens, T., Mortier, G., Beysen, D., Vandenbroucke, I., Van Roy, N., Speleman, F., & Paepe, A. D. (2000) · Human Mutation · doi:10.1002/1098-1004(200006)15:6<541::aid-humu6>3.0.co;2-n · Cited by 521
Bax, L., Yu, L.-M., Ikeda, N., Tsuruta, H., & Moons, K. G. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-50 · Cited by 514
Cited by
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Miettinen, M. M., Antonescu, C. R., Fletcher, C. D. M., Kim, A., Lazar, A. J., Quezado, M. M., Reilly, K. M., Stemmer-Rachamimov, A., Stewart, D. R., Viskochil, D., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.010 · Cited by 439
Malignant Peripheral Nerve Sheath Tumors
Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0328 · Cited by 354
Abdominal neoplastic manifestations of neurofibromatosis type 1
Dare, A. J., Gupta, A. A., Thipphavong, S., Miettinen, M., & Gladdy, R. A. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa032 · Cited by 27
Metadata
- Authors
- Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-15
- Volume
- 15
- Issue
- 2
- Pages
- 135-147
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2115632196
- Cited by
- 270
- References
- 69
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. https://app.cochat.ai/papers/10.1093/neuonc/nos287
- The paper
- Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013). Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology. https://doi.org/10.1093/neuonc/nos287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.